Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[haysaw]

do you doubt Dr Crawford's discussion of positive results for treatment of TBI in animal models?

No. Now ask me how meaningfully that correlates to human models at this point?

Dr Crawford is the Head of the nationally recognized Roskamp institute, a leading AZ and brain disease research facility, non profit by the way

There is a caveat: Roskamp was profiting off of the sale of anatabloc when it was being sold as a supplement. Do you recall that?:

http://www.richmond.com/business/local/article_17d46e14-e115-58ea-a491-b71b5d72a839.html

Much of the research on Anatabloc has been done by the Roskamp Institute, a private research institution in Sarasota, Fla., that focuses on neuropsychiatric and neurodegenerative disorders and addictions.
Star Scientific announced a research partnership with the institute in April 2010, saying that the goal of the venture “is to work as fast as possible to bring to market the first product capable of halting Alzheimer’s and other neurological diseases.”

In the same release, the company suggested that Williams, its CEO, stumbled upon anatabine’s beneficial properties during the years when Star Scientific was selling tobacco products and attempting to find ways of reducing harmful chemicals in tobacco.

“Jonnie R. Williams’ decade-long search for innovative ways to reduce tobacco-related harm fortuitously led to a discovery of a compound that respected and knowledgeable medical researchers at Roskamp Institute believe could play a major role in addressing a variety of neurological conditions, including Alzheimer’s disease,” the company’s president, Paul Perito, said in an April 7, 2010, release.

The Roskamp Institute has performed anatabine studies under a research and royalty agreement with Star Scientific. The company pays royalties of 5 percent of its Anatabloc sales to a for-profit affiliate of the institute.
The affiliate, SRQ Bio LLC, was issued 100,000 shares of Star Scientific stock in April 2010. In 2010 and 2011, Robert G. Roskamp, the founder of the Roskamp Institute, bought thousands of shares of Star Scientific’s common stock, according to regulatory filings.
In October 2010, the Roskamp Institute announced that it was starting clinical trials for the treatment of Alzheimer’s disease using RCP-006, a compound developed by Rock Creek Pharmaceuticals.
Laboratory tests showed that the RCP-006 compound “inhibits inflammation and the production of amyloid, both of which cause Alzheimer’s disease,” the institute said.
“Previous studies have shown that certain tobacco components may be protective against Alzheimer’s disease, but the mechanism was unknown, and the negative effects of smoking and tobacco use outweigh these positive benefits,” the institute said.
Since the announcement of the initial research agreement with the Roskamp Institute, Star Scientific has put out a number of news releases touting positive results in the institute’s studies of anatabine.
Those announcements included the publication of a peer-reviewed article in the European Journal of Pharmacology in October 2011 in which Roskamp scientists described how anatabine, when given to laboratory mice, reduced the amounts of a substance called A-beta that leads to brain tissue damage.
In October 2012, Roskamp researchers presented findings at the annual meeting of the Society for Neuroscience, showing that anatabine could help lessen or reverse the effects of certain neurological conditions, at least in laboratory mice.
In one presentation at the New Orleans meeting, the researchers described a study in which mice were induced to have symptoms similar to Alzheimer’s disease. The mice that were given anatabine “retained their memory and learning compared to untreated Alzheimer’s mice,” Star Scientific said.
In another presentation, Roskamp researchers said that lab mice with traumatic brain injuries had a less severe loss of spatial memory when given anatabine. The researchers said that may have been because anatabine reduced inflammation.

Do you disagree with Dr Paul Ladenson of Johns Hopkins, a nationally recognized expert and researcher on endocrine disease,when he stated that "anatabine is the only thing that ameliorates Hashimoto's Thyroiditis?

I can't disagree, but I must question it. Why isn't this the runaway, primary shot on goal for Rock Creek Pharm, given the purported substantial outcome of this trial? It would seem like a no-brainer that they would take this 'evidence' and run with it.